Related Experiment Videos
Genetics of antiphospholipid syndrome
T Atsumi1, M L Bertolaccini, T Koike
1Department of Medicine II, Hokkaido University School of Medicine, Sapporo, Japan. at3tat@med.hokudai.ac.jp
Rheumatic Diseases Clinics of North America
|September 6, 2001
Summary
Genetic variants in beta 2-glycoprotein I (beta 2GPI) may increase the risk of antiphospholipid syndrome (APS) and associated antibodies. However, beta 2GPI deficiency does not appear to raise thrombosis risk in APS patients.
Area of Science:
- Immunology
- Genetics
- Hematology
Background:
- Antiphospholipid syndrome (APS) involves complex thrombosis mechanisms.
- Genetic factors are implicated in APS pathophysiology.
- Beta 2-glycoprotein I (beta 2GPI) is a key antigen in APS.
Purpose of the Study:
- To investigate the role of genetic variants of beta 2GPI in APS.
- To determine if specific beta 2GPI polymorphisms are associated with thrombosis risk in APS.
Main Methods:
- Analysis of genetic variants, specifically the valine/leucine247 polymorphism of beta 2GPI.
- Investigation of the association between beta 2GPI deficiency and thrombophilia.
Main Results:
- The valine/leucine247 polymorphism of beta 2GPI is a genetic risk factor for anti-beta 2GPI antibodies and APS.
- Congenital beta 2GPI deficiency was not correlated with thrombophilia.
- No additional thrombosis risk was identified in APS patients with other investigated genetic factors.
Conclusions:
- Specific genetic variants of beta 2GPI, like the valine/leucine247 polymorphism, contribute to APS risk.
- Beta 2GPI deficiency does not confer a thrombosis risk in APS.
- Further research into genetic factors in APS is warranted.